DOCSLIB.ORG

The Development of a Clinical Trial Protocol and Functional Biomarkers for Age-Related Macular Degeneration

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Development of a Clinical Trial Protocol and Functional Biomarkers for Age-Related Macular Degeneration The Development of a Clinical Trial Protocol and Functional Biomarkers for Age-Related Macular Degeneration Claire McKeague A thesis submitted to Cardiff University for the degree of Master of Philosophy SCHOOL OF OPTOMETRY AND VISION SCIENCES, CARDIFF UNIVERSITY 2014 SUPERVISED BY DR ALISON BINNS & DR TOM MARGRAIN DECLARATION This work has not previously been accepted in substance for any degree and is not concurrently submitted in candidature for any degree. STATEMENT 1 This thesis is being submitted in partial fulfillment of the requirements for the degree of …………………………(insert MCh, MD, MPhil, PhD etc, as appropriate) STATEMENT 2 This thesis is the result of my own independent work/investigation, except where otherwise stated. Other sources are acknowledged by explicit references. STATEMENT 3 I hereby give consent for my thesis, if accepted, to be available for photocopying and for inter- library loan, and for the title and summary to be made available to outside organisations. Summary Age-related macular degeneration (AMD) is the leading cause of blindness amongst older adults in the developed world. With the predicted rise in the ageing population over the next decades, the prevalence of this debilitating disease will simply continue to increase. The only treatments currently available are for advanced neovascular AMD. The retina is already severely compromised by this stage in disease development. Therefore, there is a pressing need to evaluate potential novel interventions that aim to prevent the development of advanced disease in people with early AMD, to prevent sight loss from occurring. Furthermore, it is necessary to develop tests that are sensitive to subtle changes in visual function in order to evaluate the efficacy of these emerging treatments. There is a growing body of evidence to suggest that hypoxia contributes to the development of AMD. Hypoxia is most acute at night when the retinal photoreceptors are most metabolically active, due to the demands of the rod dark current. Increasing the light levels at night will cause the oxygen demand, and hence the hypoxia, to be substantially diminished. This leads to the hypothesis that providing low level night time light therapy to people with early AMD may slow disease progression by reducing hypoxia. In order to evaluate the potential effectiveness of such an intervention, it is necessary to select appropriate outcome measures. The inherent variability of the standard test of visual function, visual acuity, renders it inappropriate for use as a primary outcome measure in proof of concept clinical trials. Therefore, the first aim of this thesis was to evaluate the diagnostic validity and repeatability of alternative functional tests that may be used as biomarkers for early macular disease. Dark adaptation was evaluated using three stimuli, a spot of 2o radius and annuli of 7o and 12o radii, in 21 healthy adults (on two occasions) and in 11 participants with early AMD. All stimuli were found to be highly diagnostic for early AMD. The spot of 2o radius provided the best separation between groups with respect to the time constant of cone recovery (area under the ROC curve 0.91). The repeatability of chromatic and flicker thresholds were also assessed in 30 healthy adults. The coefficient of repeatability, expressed as a percentage of the mean threshold, was 17.1% for red-green chromatic thresholds, 31.1% for blue-yellow, 53.4% for 14Hz flicker thresholds, and ranged between 36.4%-53.3% for parameters of dark adaptation. A small learning iii effect was found for both chromatic thresholds and the 14-Hz flicker test, indicating that a control group is needed in studies of new therapeutic interventions. The second aim of this thesis was to develop a protocol for a clinical trial that seeks to determine if low level night time light therapy can prevent the progression of early AMD. The level of retinal illuminance required to suppress the rod dark current, the maximum retinal illuminance which prevents substantial suppression of melatonin secretion, and the most appropriate means of delivering the dose of retinal illumination were evaluated. The final protocol employed an organic LED illuminated light mask, worn during hours of sleep, as the mode of intervention. In conclusion, this thesis has confirmed that cone dark adaptation is a sensitive functional biomarker for AMD, and that all three functional tests have a good inter- session repeatability. These biomarkers will be validated in the prospective clinical trial of low-level light therapy to confirm their prognostic and predictive capabilities. The proposed trial will also evaluate the effectiveness of the low level night time light therapy, delivered by means of an illuminated light mask, at slowing the progression of early AMD. iv Acknowledgements First and foremost, I give thanks to my Saviour Jesus Christ for giving me the knowledge, understanding and strength to undertake and complete this research project. Having spent two years studying just one aspect of the human eye, I have only begun to scratch the surface in understanding its intricate design, and am in awe of the power and wisdom of God and His amazing creation! I would also like to express my deepest gratitude to my wonderful supervisors, Dr Alison Binns and Dr Tom Margrain, for their continual guidance and support at all stages of this research project. I am greatly indebted to them for all the time they have devoted to helping me, and feel honoured to have worked with them over the past two years. I am grateful to all the lovely participants in my studies that have given up their time to provide the data presented in this thesis, with only the promise of a cup of tea and a light at the end of the tunnel! Thank you to all my friends in room 2.10 for helping me perfect the art of procrastination. Thank you to the Eye Clinic staff for all their help throughout this time. Furthermore, a special thank you to Sue and all the lovely staff in the Optometry building for all their help and support. They put a smile on my face every day! Lastly, I would like to thank my family for their constant love, support and encouragement over the past two years. Without them, this work would not have been accomplished. Amazing grace, how sweet the sound That saved a wretch like me. I once was lost but now am found, Was blind but now I see. v Table of Contents Summary ..................................................................................................................... iii Acknowledgements ...................................................................................................... v List of Figures .............................................................................................................. ix List of Tables ............................................................................................................. xii List of Equations ...................................................................................................... xiii 1. Introduction .......................................................................................................... 1 1.1 General Introduction .................................................................................................... 1 1.2 The Healthy Retina ....................................................................................................... 1 1.2.1 Overview of the Retina ............................................................................................ 1 1.2.2 Bruch’s Membrane .................................................................................................. 3 1.2.3 The Retinal Pigment Epithelium .............................................................................. 4 1.2.4 Photoreceptor cells ................................................................................................... 5 1.2.5 The Macula .............................................................................................................. 6 1.2.6 Blood Supply to the Retina ...................................................................................... 7 1.3 Age-Related Macular Degeneration ............................................................................ 9 1.3.1 Background .............................................................................................................. 9 1.3.2 Clinical Classification ............................................................................................ 10 1.3.3 Clinical features of AMD ...................................................................................... 10 1.3.4 Grading scales for severity of AMD ...................................................................... 12 1.3.5 Risk Factors for the Development of AMD ........................................................... 14 1.3.6 Clinical Assessment of AMD ................................................................................ 17 1.3.7 Pathogenesis of AMD ............................................................................................ 22 1.3.8 Management .......................................................................................................... 26 1.4 Hypoxia and AMD ...................................................................................................... 29 1.4.1 Oxygen Demand of the Retina ............................................................................... 29 1.4.2 Oxygen Supply to the Retina ................................................................................
Load more

Recommended publications
  • Characterising Adaptational Dysfunction in Age-Related Macular Degeneration
    Characterising adaptational dysfunction in age-related macular degeneration A thesis submitted to Cardiff University for the degree of Doctor of Philosophy By Allannah Jayne Gaffney School of Optometry and Vision Sciences Cardiff University August 2012 Supervised by Dr Alison Binns and Dr Tom Margrain Summary Age-related macular degeneration (AMD) is the leading cause of visual impairment in the developed world (Resnikoff et al., 2004). The prevalence of this disease will continue to increase over the coming decades as the average age of the global population rises (United Nations, 2009). There is consequently an urgent need to develop tests that are sensitive to early visual dysfunction, in order to identify individuals that have a high risk of developing AMD, to identify patients that would benefit from treatment, to assess the outcomes of that treatment and to evaluate emerging treatment strategies. An emerging body of evidence suggests that dark adaptation is a sensitive biomarker for early AMD. Cone dark adaptation is of particular interest to clinicians, as it can identify patients with early AMD in a relatively short recording period. Consequently, this thesis aimed to optimise psychophysical and electrophysiological techniques for the assessment of cone dark adaptation in early AMD, in order to maximise its diagnostic potential. A range of psychophysical methods were shown to be capable of monitoring the rapid changes in threshold that occur during cone dark adaptation. An optimal psychophysical protocol for the assessment of cone dark adaptation in early AMD was developed based on the results of a systematic evaluation of the effect of stimulus parameters and pre-adapting light intensity on the diagnostic potential of cone dark adaptation in early AMD.
    [Show full text]
  • Visual Predictors for Poor Mobility Performance in People with Age Related Macular Degeneration
    VISUAL PREDICTORS FOR POOR MOBILITY PERFORMANCE IN PEOPLE WITH AGE RELATED MACULAR DEGENERATION Remy Sheena Mathew, B.Sc A thesis submitted in partial fulfilment of the requirements for admission to the degree of Doctor of Philosophy School of Optometry and Vision Science, University of New South Wales, Sydney, Australia September 2009 Visual predictors for poor mobility performance in people with AMD Originality statement ‘I hereby declare that this submission is my own work and to the best of my knowledge it contains no materials previously published or written by another person, or substantial proportions of material which have been accepted for the award of any other degree or diploma at UNSW or any other educational institution, except where due acknowledgement is made in the thesis. Any contribution made to the research by others, with whom I have worked at UNSW or elsewhere, is explicitly acknowledged in the thesis. I also declare that the intellectual content of this thesis is the product of my own work, except to the extent that assistance from others in the project's design and conception or in style, presentation and linguistic expression is acknowledged.’ Signed …………………………...................... Remy Sheena Mathew. ii Visual predictors for poor mobility performance in people with AMD Copyright and Authenticity Statements COPYRIGHT STATEMENT ‘I hereby grant the University of New South Wales or its agents the right to archive and to make available my thesis or dissertation in whole or part in the University libraries in all forms of media, now or here after known, subject to the provisions of the Copyright Act 1968.
    [Show full text]
  • Prevalence and Quantification of Geographic Atrophy Associated With
    Downloaded from http://bjo.bmj.com/ on August 18, 2017 - Published by group.bmj.com Clinical science Prevalence and quantification of geographic atrophy associated with newly diagnosed and treatment- naïve exudative age-related macular degeneration Anne Sikorav,1 Oudy Semoun,1 Sandrine Zweifel,2 Camille Jung,3 Mayer Srour,1 Giuseppe Querques,1,4 Eric H Souied1 10–14 ► Additional material is ABSTRACT develop, causing further vision loss. Most published online only. To view Objective To identify and quantify geographic atrophy studies focus on either wet or dry form separately please visit the journal online (GA) associated with neovascular age-related macular and there is a paucity of reports on both forms of (http:// dx. doi. org/ 10. 1136/ bjophthalmol- 2015- 308065). degeneration (AMD) at initial presentation using a AMD concomitantly in the same eye. There are fundus autofluorescence (FAF) semi-automated software recent published data regarding the prevalence of – 1Department of Ophthalmology, and to correlate the results with demographic and GA complicating exudative AMD at diagnosis,14 16 University Paris Est, Centre clinical data. with diverse results. Hospitalier Intercommunal de Creteil, Creteil, France Design Retrospective, observational study. In both atrophic and exudative AMDs, RPE 2Department of Ophthalmology, Methods The study population consisted of treatment- damage may be an important factor for visual loss. University Hospital Zurich, naïve patients with newly diagnosed neovascular AMD. The status of RPE can be studied by blue light Zurich, Switzerland Best-corrected visual acuity, fundus photographs, infrared fundus autofluorescence (FAF) imaging, which is a 3 Clinical Research Center, reflectance, FAF and spectral-domain optical coherence non-invasive imaging method that allows for topo- University Paris Est fl Creteil, Centre Hospitalier tomography were performed, associated with uorescein graphic mapping of lipofuscin distribution in the 17 18 intercommunal de Creteil, and indocyanine green angiographies.
    [Show full text]
  • The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration
    The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration Monika Fleckenstein, MD,1 Paul Mitchell, MD, PhD,2 K. Bailey Freund, MD,3,4 SriniVas Sadda, MD,5,6 Frank G. Holz, MD,1 Christopher Brittain, MBBS,7 Erin C. Henry, PhD,8 Daniela Ferrara, MD, PhD8 Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that leads to pro- gressive and irreversible loss of visual function. Geographic atrophy is defined by the presence of sharply demarcated atrophic lesions of the outer retina, resulting from loss of photoreceptors, retinal pigment epithelium (RPE), and underlying choriocapillaris. These lesions typically appear first in the perifoveal macula, initially sparing the foveal center, and over time often expand and coalesce to include the fovea. Although the kinetics of GA progression are highly variable among individual patients, a growing body of evidence suggests that specific characteristics may be important in predicting disease progression and outcomes. This review synthesizes current understanding of GA progression in AMD and the factors known or postulated to be relevant to GA lesion enlargement, including both affected and fellow eye characteristics. In addition, the roles of genetic, environ- mental, and demographic factors in GA lesion enlargement are discussed. Overall, GA progression rates reported in the literature for total study populations range from 0.53 to 2.6 mm2/year (median, w1.78 mm2/year), assessed primarily by color fundus photography or fundus autofluorescence (FAF) imaging. Several factors that could inform an individual’s disease prognosis have been replicated in multiple cohorts: baseline lesion size, lesion location, multifocality, FAF patterns, and fellow eye status.
    [Show full text]
  • Specialist Clinic Referral Guidelines OPHTHALMOLOGY
    Specialist Clinic Referral Guidelines OPHTHALMOLOGY COVID-19 Impact — Specialist Clinics As part of Alfred Health’s COVID-19 response plan, from October significant changes have been made to Specialist Clinic (Outpatient) services. All referrals received will be triaged; however, if your patient’s care is assessed as not requiring an appointment within the next three months, the referral may be declined. Where possible, care will be delivered via telehealth (phone or video consultation). Please fax your referral to The Alfred Specialist Clinics on 9076 6938. The Alfred Outpatient Referral Form is available to print and fax. Where appropriate and available, the referral may be directed to an alternative specialist clinic or service. You will be notified when your referral is received. Your referral may be declined if it does not contain essential information required for triage, or if the condition is not appropriate for referral to a public hospital, or is a condition not routinely seen at Alfred Health. The clinical information provided in your referral will determine the triage category. The triage category will affect the timeframe in which the patient is offered an appointment. Referral to Victorian public hospitals is not appropriate for: Review or treatment of neovascular (wet) age-related macular degeneration (AMD) where the patient has already commenced treatment at another facility Early intermediate or geographic atrophy (dry) age-related macular degeneration. If the patient is not willing to have surgical treatment Cataract that does not have a significant impact on the person’s activities of daily living Prior to the person’s vision being corrected with spectacles, contact lenses, or the use of visual aids.
    [Show full text]
  • INHERITED RETINAL DISEASE ¨ Hundreds of Causative Mutations Now Identified ¤ Most Affecting Photoreceptors Or RPE
    9/4/18 Hereditary Retinal Diseases Epidemiology ¨ HRDs affect about 1/2000 people worldwide INHERITED RETINAL DISEASE ¨ Hundreds of causative mutations now identified ¤ Most affecting photoreceptors or RPE ¨ Many associated with systemic syndromes Blair Lonsberry, MS, OD, MEd., FAAO ¨ Most cause significant visual disability Professor of Optometry Pacific University College of Optometry [email protected] ! Hereditary Retinal Disease! The Rod/Cone Dichotomy ! Signs and Symptoms Based on Photoreceptors Peripheral (Rod) Diseases Central (Cone) Diseases ! Involved: ¨ Retinitis Pigmentosa family ¨ Achromatopsia ! ¤ Leber’s Congenital Amaurosis ¨ Cone Dystrophy RODS CONES ¨ CSNB • Loss of Night Vision • Decreased Acuity ¨ Oguchi’s ¨ Stargardt’s juvenile • Peripheral Field Loss • Central scotoma macular ¨ Best’s dystrophies • ERG: Scotopic loss • ERG: Photopic loss • VA and color vision affected late • Color Vision Affected •Photosensitivity • Photosensitivity Case History/Entrance Skills Health Assessment 5 6 ¨ 31 YR HM ¨ SLE: ¨ CC: referred from PCP for a possible uveitis ¤ 1+ conjunctival injection in the right eye ¨ LEE: 3 years ago ¤ Anterior chamber: deep and quiet (no cells or flare ¨ PMHx: unremarkable noted in either eye) ¨ Meds: Omega-3 supplements ¨ Entrance VA: 20/30+ OD, OS ¨ IOP: 12 and 11 OD, OS ¨ Refraction: ¨ DFE: see photos ¤ +0.75 -2.50 x 003 6/7.5+ (20/25+) ¤ +0.25 -2.75 x 004 6/7.5+ (20/25+) ¨ All other entrance skills unremarkable except for difficulty doing confrontation visual fields 1 9/4/18 OS 7 OS OD 8 OD Retinitis
    [Show full text]
  • Visual Impairment Age-Related Macular
    VISUAL IMPAIRMENT AGE-RELATED MACULAR DEGENERATION Macular degeneration is a medical condition predominantly found in young children in which the center of the inner lining of the eye, known as the macula area of the retina, suffers thickening, atrophy, and in some cases, watering. This can result in loss of side vision, which entails inability to see coarse details, to read, or to recognize faces. According to the American Academy of Ophthalmology, it is the leading cause of central vision loss (blindness) in the United States today for those under the age of twenty years. Although some macular dystrophies that affect younger individuals are sometimes referred to as macular degeneration, the term generally refers to age-related macular degeneration (AMD or ARMD). Age-related macular degeneration begins with characteristic yellow deposits in the macula (central area of the retina which provides detailed central vision, called fovea) called drusen between the retinal pigment epithelium and the underlying choroid. Most people with these early changes (referred to as age-related maculopathy) have good vision. People with drusen can go on to develop advanced AMD. The risk is considerably higher when the drusen are large and numerous and associated with disturbance in the pigmented cell layer under the macula. Recent research suggests that large and soft drusen are related to elevated cholesterol deposits and may respond to cholesterol lowering agents or the Rheo Procedure. Advanced AMD, which is responsible for profound vision loss, has two forms: dry and wet. Central geographic atrophy, the dry form of advanced AMD, results from atrophy to the retinal pigment epithelial layer below the retina, which causes vision loss through loss of photoreceptors (rods and cones) in the central part of the eye.
    [Show full text]
  • Normative Value of Photostress Recovery Time Among Various Age Groups in Southern India
    Medical Hypothesis, Discovery &Innovation Optometry Journal Original Article Normative value of photostress recovery time among various age groups in southern India Bhandari Bishwash 1 , De Tapas Kumar 1, Sah Sanjay Kumar 1, Sanyam Sandip Das 1 1 Sankara Academy of Vision, Sankara College of optometry, Bangalore, India ABSTRACT Background: To determine the normative data and reference value for photostress recovery time (PSRT) following exposure of the macula to light, in various age groups within the Indian population. Methods: Cross-sectional observational study performed from November 2015 to July 2016 in the Bangalore district of Karnataka state in India. We examined a total of 1,282 eyes of 641 participants and included those with corrected distance visual acuity (CDVA) scoes lower than or equal to 0.4 Logarithm of the Minimum Angle of Resolution (LogMAR). We performed the photostress procedure under standard conditions using the same approach. Results: The mean ± standard deviation (SD) of the participants’ age was 32.04 ± 15.80, with an age range of 8 to 70 years. The PSRT in participants below 16 years and above 45 years of age were significantly different compared to the 16–25-year-old age group (P < 0.0001 for both). The PSRT values were significantly different between males and females in the reproductive age group (16 to 45 years old) (P < 0.0001), but not in the other age groups. Conclusions: The PSRT values were significantly different in children and older patients compared to the 16 to 25 years age group. We found that as age increased, PSRT increased significantly.
    [Show full text]
  • Polypoidal Choroidal Vasculopathy-Associated Vitreous Haemorrhage Presenting As Hyphema Srikanta Kumar Padhy, Atul Kumar, Rebika Dhiman, Karen Sharma
    Images in… BMJ Case Rep: first published as 10.1136/bcr-2018-227547 on 13 December 2018. Downloaded from Polypoidal choroidal vasculopathy-associated vitreous haemorrhage presenting as hyphema Srikanta Kumar Padhy, Atul Kumar, Rebika Dhiman, Karen Sharma Dr Rajendra Prasad Centre for DESCRIPTION Ophthalmic Sciences, All India A 59-year-old Indian male patient presented to our Institute of Medical Sciences, clinic with sudden-onset, painless diminution of New Delhi, Delhi, India vision in the right eye for the last 1 week. Records from previous follow-up (2 months back) showed Correspondence to Dr Srikanta Kumar Padhy, that his vision was 20/200 right eye (OD) and 20/80 srikantkumar. padhy19@ gmail. left eye (OS). He had no known systemic medical com conditions. He was diagnosed as a case of right eye pseudophakia with polypoidal choroidal vascu- Accepted 13 November 2018 lopathy (figure 1A), as evidenced by his previous fundus fluorescein angiography (FFA) (figure 1B), indocyanine green angiography (ICGA) (figure 1C) and swept source optical coherence tomography (SSOCT) (figure 2A,C). He has been on regular follow-up for the same condition for the past 4 years. During the course, he had received four intravitreal antivascular endothelial growth factor (anti-VEGF, aflibercept 2 mg in 0.05 mL) injections, with the last injection being administered 4 months back. On ocular examination, his best-corrected visual acuity was hand movement close to face OD and 20/80 OS. Intraocular pressure was 16 mm Hg OD Figure 2 (A,C) Swept source optical coherence and 14 mm Hg OS. On slit lamp examination, pres- tomography (SSOCT) imaging of the right eye showing ence of hyphema (figure 3A) was noted in the right thumb-shaped pigment epithelial detachment (long eye obscuring the details of the rest of the ante- arrow) with double-layer sign (short arrow).
    [Show full text]
  • Cellular Functional Architecture of the Human Cone Photoreceptor Mosaic
    Cellular Functional Architecture of the Human Cone Photoreceptor Mosaic By William Scott Tuten A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Vision Science in the Graduate Division of the University of California, Berkeley Committee in charge: Professor Austin Roorda, Chair Professor Susana Chung Professor Gerald Westheimer Fall 2014 Cellular Functional Architecture of the Human Cone Photoreceptor Mosaic © 2014 by William Scott Tuten Abstract Cellular Functional Architecture of the Human Cone Photoreceptor Mosaic by William Scott Tuten Doctor of Philosophy in Vision Science University of California, Berkeley Professor Austin Roorda, Chair Chromatic and high-acuity aspects of vision are mediated by cone photoreceptors, which sample the image relayed by the eye’s optics and transduce it into the neural signals that give rise to perception. Our understanding of how individual cones function has largely been gleaned from in vitro electrophysiological preparations, which allow the experimenter to stimulate single receptors while simultaneously recording their outputs. Building upon these findings requires investigating how signals arising from single sensory input neurons are handled downstream by the nervous system, up to and including the perceptual stage. With these goals in mind, the tools to approach these questions in vivo must be developed. The challenges associated with studying the perceptions arising from single sensory receptors are not trivial—doing so requires an ability to visualize and repeatedly stimulate the receptor of interest, which can be difficult when it is situated within a densely packed array of similar cells that is itself contained within a sensory organ. The eye, however, represents a unique case because the receptor layer can be visualized directly through the transparent cornea and lens.
    [Show full text]
  • Common Eye Disorders in the Elderly – a Short Review
    CPD Article Common eye disorders in the elderly – a short review Visser L, FCOphth(SA), MMed(Ophth) Acting Head of Department of Ophthalmology, Nelson R Mandela School of Medicine, University of KwaZulu-Natal Correspondence to: Dr Linda Visser, e-mail [email protected] Abstract As the eye ages, certain changes occur that may affect vision. Presbyopia is corrected by the use of reading glasses. Cataracts are common and vision can be restored following a reasonably simple operation. Visual loss due to glaucoma can be minimised by early detection and treatment, but once vision has been lost it cannot be recovered. Much research is being done on the treatment of age-related macular degeneration, but this currently remains the main cause of irreversible loss of vision in the elderly. Results of macular hole surgery are improving due to improved surgical techniques and better diagnostic equipment (Optical Coherence Tomography). Underlying vascular disease (systemic hypertension, diabetes, atherosclerosis, vasculitis) is usually present in patients with retinal artery occlusion, retinal vein occlusion or anterior ischaemic optic neuropathy. SA Fam Pract 2006;48(7): 34-38 Introduction of treatment has been measured in is the most common and one of the Loss of vision in the elderly can have terms of less loss of vision rather than earlier age-related disorders of the a multitude of causes. Often the a gain in vision. Recent advances in eyes. Symptoms of presbyopia usu- remedy is simple, for example pre- the treatment of AMD with intraocu- ally begin between the ages of 40 scribing spectacles (as in the case lar injections are however showing and 45 years, although they may be- of presbyopia) or a reasonably small promise with many patients regain- gin earlier in hyperopes (farsighted operation (as in the case of cata- ing some of the vision initially lost.
    [Show full text]
  • Related Macular Degeneration Perhaps You Have Just Learned That You Or a Loved One Has Age-Related Macular Degeneration, Also Known As AMD
    What you should know about age- related macular degeneration Perhaps you have just learned that you or a loved one has age-related macular degeneration, also known as AMD. If you are like many people, you probably do not know a lot about the condition or understand what is going on inside your eyes. What is AMD? AMD is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small spot near the center of the retina and the part of the eye needed for sharp, central vision, which lets us see objects that are straight ahead. In some people, AMD advances so slowly that vision loss does not occur for a long time. In others, the disease progresses faster and may lead to a loss of vision in one or both eyes. As AMD progresses, a blurred area near the center of vision is a common symptom. Over time, the blurred area may grow larger or you may develop blank spots in your central vision. Objects also may not appear to be as bright as they used to be. AMD can also interfere with simple everyday activities, such as the ability to see faces, drive, read, write, or do close work, such as cooking or fixing things around the house. The Macula The macula is made up of millions of light-sensing cells that provide sharp, central vision. It is the most sensitive part of the retina, which is located at the back of the eye.
    [Show full text]